Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boehringer Ingelheim
Biotech
Boehringer pays €25M for option to Sosei’s schizophrenia drug
Boehringer has secured an opportunity to beef up its schizophrenia portfolio courtesy of a €25 million ($27.3 million) deal with Sosei Heptares.
James Waldron
Mar 11, 2024 9:10am
Boehringer links GLP-1 agonist to scarring improvements in MASH
Feb 26, 2024 6:17am
Surrozen stops IBD program due to dose concerns and competition
Jan 18, 2024 9:55am
Boehringer ends week with 3rd deal, this time with Kyowa Kirin
Jan 5, 2024 10:34am
Boehringer inks second 3T deal, swelling max payday to $538.5M
Jan 4, 2024 7:45am
Boehringer bets $2B in biobucks on siRNA treatments for MASH
Jan 3, 2024 6:00am